Diploma (DPLM) Competitors

Diploma (LON:DPLM) and Dechra Pharmaceuticals (LON:DPH) are both mid-cap industrials companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Is DPLM or DPH a better dividend stock?

Diploma pays an annual dividend of GBX 57 per share and has a dividend yield of 1.3%. Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. Diploma pays out 6,627.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend.

Which has preferable earnings and valuation, DPLM or DPH?

Diploma has higher revenue and earnings than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than Diploma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diploma	£1.26B	4.84	£116.10M	£0.86	5,293.02
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A

Is DPLM or DPH more profitable?

Diploma has a net margin of 9.25% compared to Dechra Pharmaceuticals' net margin of -3.66%. Diploma's return on equity of 13.39% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diploma	9.25%	13.39%	8.32%
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%

Does the MarketBeat Community prefer DPLM or DPH?

Dechra Pharmaceuticals received 62 more outperform votes than Diploma when rated by MarketBeat users. Likewise, 63.00% of users gave Dechra Pharmaceuticals an outperform vote while only 61.71% of users gave Diploma an outperform vote.

Company	Underperform	Outperform
Diploma	Outperform Votes 282 61.71%	Underperform Votes 175 38.29%
Dechra Pharmaceuticals	Outperform Votes 344 63.00%	Underperform Votes 202 37.00%

Which has more risk and volatility, DPLM or DPH?

Diploma has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.

Does the media prefer DPLM or DPH?

In the previous week, Diploma had 1 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 1 mentions for Diploma and 0 mentions for Dechra Pharmaceuticals. Diploma's average media sentiment score of 0.17 beat Dechra Pharmaceuticals' score of 0.00 indicating that Diploma is being referred to more favorably in the media.

Company	Overall Sentiment
Diploma	Neutral
Dechra Pharmaceuticals	Neutral

Do institutionals & insiders have more ownership in DPLM or DPH?

81.5% of Diploma shares are owned by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are owned by institutional investors. 0.5% of Diploma shares are owned by company insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts prefer DPLM or DPH?

Diploma presently has a consensus price target of GBX 4,567.50, indicating a potential upside of 0.34%. Given Diploma's stronger consensus rating and higher possible upside, equities analysts plainly believe Diploma is more favorable than Dechra Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diploma	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Dechra Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Diploma beats Dechra Pharmaceuticals on 13 of the 19 factors compared between the two stocks.